NCT01617681 - Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD | Biotech Hunter

Enrollment

127

Participants

Timeline

Start Date

November 8, 2012

Primary Completion Date

January 24, 2017

Study Completion Date

January 24, 2017

Conditions

Pediatric Hypertension With or Without CKD

Interventions

DRUG

VAL489

Valsartan 3mg/kg oral solution

DRUG

VAL489 matching placebo

Valsartan 3 mg/kg oral solution

Trial Locations (27)

1010

Novartis Investigative Site, Guatemala City

2020

Novartis Investigative Site, Antwerp

4000

Novartis Investigative Site, Liège

6725

Novartis Investigative Site, Szeged

13353

Novartis Investigative Site, Berlin

20097

Novartis Investigative Site, San Donato Milanese

34059

Novartis Investigative Site, Montpellier

35039

Novartis Investigative Site, Marburg

40138

Novartis Investigative Site, Bologna

90134

Novartis Investigative Site, Palermo

80250-060

Novartis Investigative Site, Curitibia

13087-567

Novartis Investigative Site, Campinas

95070-561

Novartis Investigative Site, Caxias do Sul

90610-000

Novartis Investigative Site, Porto Alegre

01001

Novartis Investigative Site, Guatemala City

01010

Novartis Investigative Site, Guatemala City

H 1096

Novartis Investigative Site, Budapest

H-1083

Novartis Investigative Site, Budapest

08406

Novartis Investigative Site, Vinius

15-274

Novartis Investigative Site, Bialystok

80-952

Novartis Investigative Site, Gdansk

30-663

Novartis Investigative Site, Krakow

93-338

Novartis Investigative Site, Lodz

20-093

Novartis Investigative Site, Lublin

61-825

Novartis Investigative Site, Poznan

71-252

Novartis Investigative Site, Szczecin

04-154

Novartis Investigative Site, Warsaw